Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived Materials to Treat and Accelerate the Healing of Wounds

HOUSTON, Sept. 3, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,721,866, titled "Therapeutic Use of Fibroblasts for Use in Wound Healing." The patent, issued on September 1, 2026, covers methods of treating and accelerating the healing of wounds by topically administering a therapeutically effective amount of a composition comprising fibroblasts and fibroblast-derived materials.